Address
Email address
Phone number
https://icosagen.eeKoduleht - IcosagenMuudame ideed reaalsuseks Icosagen on pühendunud Eesti biotehnoloogiaettevõte, mis tegeleb terapeutiliste antikehade arendamise ja diagnostiliste rekombinantsete valkude tootmisega imetajate rakkudes nii teadusuuringute kui ka in vitro diagnostika tarbeks. Loe lisaks Meist Teenused Klientide tagasiside “Fast responses, great flexibility, transparency, collaborative spirit, high quality” Ridgeline Kliki siia”Fast reply, quality of reports, good product profile” Pharis Biofarmaceuticals […]
Name
Amplikon OÜ
Registry code
12860392
VAT number
EE102547775
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
03.06.2015 (9)
Financial year
01.01-31.12
Capital
3 000.00 €
Activity
69202 - Bookkeeping, tax consulting
14 469 106 €
2 490 040 €
17%
2 945 €
(estimate is approximate)
22 896 788 €
167
Submitted
No tax arrears
11%
8%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Mart Ustav 16.07.1949 (75) | 100% - 3 000.00 EUR | Board member | Direct ownership | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Icosagen AS 10565884 | 96% - 184 838.40 EUR | - | - | Shareholder |
| 2019 16.07.2020 | 2020 28.12.2021 | 2021 08.07.2022 | 2022 29.06.2023 | 2023 21.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 5 949 254 € | 8 736 977 € | 13 150 460 € | 14 764 667 € | 14 469 106 € |
| Net profit (loss) for the period | 983 558 € | 2 846 913 € | 6 701 089 € | 6 157 769 € | 2 490 040 € |
| Profit Margin | 17% | 33% | 51% | 42% | 17% |
| Current Assets | 3 333 242 € | 1 502 € | 12 642 191 € | 15 036 904 € | 8 448 693 € |
| Fixed Assets | 3 534 650 € | 4 101 103 € | 4 627 224 € | 11 029 647 € | 24 104 249 € |
| Total Assets | 6 867 892 € | 10 091 330 € | 17 269 415 € | 26 066 551 € | 32 552 942 € |
| Current Liabilities | 1 114 669 € | 7 687 € | 1 881 134 € | 4 096 851 € | 5 952 863 € |
| Non Current Liabilities | 1 336 170 € | 601 110 € | 1 417 361 € | 1 717 544 € | 3 703 291 € |
| Total Liabilities | 2 450 839 € | 608 797 € | 3 298 495 € | 5 814 395 € | 9 656 154 € |
| Share Capital | - | - | - | - | - |
| Equity | 4 417 053 € | 7 263 241 € | 13 970 920 € | 20 252 156 € | 22 896 788 € |
| Employees | 63 | 69 | 92 | 132 | 167 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 18 989.29 € | 11 968.07 € | 8 923.59 € | - |
| 2023 Q4 | 15 044 € | 8 618.24 € | 6 119.04 € | 1 |
| 2023 Q3 | 19 231 € | 8 932.47 € | 5 859.95 € | 1 |
| 2023 Q2 | 19 685 € | 11 808.61 € | 8 695.99 € | 1 |
| 2023 Q1 | 19 392 € | 9 552.75 € | 6 461.13 € | 1 |
| 2022 Q4 | 13 585 € | 7 390.5 € | 5 189.33 € | 1 |
| 2022 Q3 | - | 5 130.76 € | 5 562.57 € | 1 |
| 2022 Q2 | - | 5 280.28 € | 5 724.68 € | 1 |
| 2022 Q1 | - | 2 520.71 € | 2 732.86 € | 1 |
| 2021 Q4 | - | - | - | 1 |
